+Compare
HSCS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
10.42M

HSCS Price Prediction, Heart Test Laboratories AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for HSCS with price predictions
07:00 PM EST Nov 30, 2023

HSCS saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for HSCS moved out of overbought territory on December 01, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 7 similar instances where the indicator exited the overbought zone. In of the 7 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSCS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HSCS broke above its upper Bollinger Band on November 28, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HSCS entered a downward trend on November 07, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HSCS's RSI Oscillator exited the oversold zone, of 7 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 20, 2023. You may want to consider a long position or call options on HSCS as a result. In of 22 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HSCS just turned positive on November 09, 2023. Looking at past instances where HSCS's MACD turned positive, the stock continued to rise in of 9 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where HSCS advanced for three days, in of 55 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.911) is normal, around the industry mean (25.181). P/E Ratio (0.000) is within average values for comparable stocks, (79.550). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.249). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. HSCS's P/S Ratio (1250.000) is very high in comparison to the industry average of (44.232).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HSCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

A.I. Advisor
published Earnings

HSCS is expected to report earnings to fall 15.38% to -10 cents per share on January 03

Heart Test Laboratories HSCS Stock Earnings Reports
Q4'23
Est.
$-0.11
Q3'23
Beat
by $0.01
Q2'23
Beat
by $0.01
Q1'23
Est.
$-0.16
Q4'22
Beat
by $0.06
The last earnings report on September 27 showed earnings per share of -12 cents, beating the estimate of -14 cents. With 5.99M shares outstanding, the current market capitalization sits at 10.42M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.4B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 4%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 704%. LNDZF experienced the highest price growth at 347%, while SDCCQ experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 107%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 69
Price Growth Rating: 60
SMR Rating: 84
Profit Risk Rating: 88
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
550 Reserve Street
Phone
+1 737 414-9213
Employees
12
Web
https://www.heartsciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PCT4.630.59
+14.60%
PureCycle Technologies
CSTE4.200.14
+3.45%
Caesarstone Ltd
TCBI56.631.75
+3.19%
Texas Capital Bancshares
DT54.821.27
+2.37%
Dynatrace
CSSE0.27-0.01
-4.40%
Chicken Soup for the Soul Entertainment

HSCS and

Correlation & Price change

A.I.dvisor tells us that HSCS and GENE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HSCS and GENE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HSCS
1D Price
Change %
HSCS100%
-7.40%
GENE - HSCS
33%
Poorly correlated
-6.18%
HSDT - HSCS
32%
Poorly correlated
+2.52%
RSLS - HSCS
27%
Poorly correlated
+2.02%
STSS - HSCS
26%
Poorly correlated
+0.04%
GMVDF - HSCS
23%
Poorly correlated
N/A
More